Inoue Hitoshi, Nonomura Norio, Kojima Yasuyuki, Shiba Masahiro, Oka Daizo, Arai Yasuyuki, Nakayama Masashi, Takayama Hitoshi, Nishimura Kazuo, Mori Hiroshi, Okuyama Akihiko
Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, and Department of Urology, Inoue Hospital, Suita, Japan.
Nephrol Dial Transplant. 2007 Jul;22(7):2052-5. doi: 10.1093/ndt/gfm184. Epub 2007 Apr 16.
Renal cell carcinoma (RCC) frequently occurs in patients with long-term dialysis. Long-term dialysis causes distinctive pathological changes in the kidney, which is known as acquired cystic disease of the kidney (ACDK). It is of great interest to know whether RCCs occurring in the dialytic kidneys harbour the same or similar mutations of the von Hippel-Lindau (VHL) gene as conventional dialysis-unrelated clear cell RCCs so often do.
Renal cancer tissues (eight clear cell, two papillary, one Bellini duct and three of the so-called dialysis-specific renal carcinomas) from 13 patients undergoing long-term dialysis were examined for somatic mutations of the VHL disease gene. By means of laser capture microdissection, cancerous and surrounding non-cancerous renal tissues from dialytic patients were subjected to PCR-based direct sequencing of the VHL gene.
Direct forward and reverse sequencing showed that three tumours possessed VHL gene mutations (713delG, 500-504del5-bp and 709A>G). These three mutations were identified in clear cell carcinomas occurring in association with end-stage renal disease undergoing dialysis for 194, 147 and 125 months. None of the non-tumour tissues or other carcinoma tissues analysed, including dialysis-specific carcinoma, possessed VHL gene mutations.
These results indicate that VHL tumour-suppressor gene mutation is involved in clear cell carcinoma in association with long-term dialysis. Mutation of the VHL gene was not found in any of the dialysis-specific RCCs studied herein.
肾细胞癌(RCC)常发生于长期透析患者。长期透析会导致肾脏出现独特的病理变化,即获得性肾囊肿病(ACDK)。了解透析肾中发生的RCC是否携带与传统非透析相关性透明细胞RCC常见的相同或相似的von Hippel-Lindau(VHL)基因突变,具有重要意义。
对13例长期透析患者的肾癌组织(8例透明细胞癌、2例乳头状癌、1例Bellini管癌和3例所谓的透析特异性肾癌)进行VHL疾病基因的体细胞突变检测。通过激光捕获显微切割技术,对透析患者的癌组织及周围非癌肾组织进行VHL基因的基于PCR的直接测序。
正向和反向直接测序显示,3个肿瘤存在VHL基因突变(713delG、500 - 504del5-bp和709A>G)。这3种突变在与终末期肾病相关的透明细胞癌中被发现,这些患者分别接受了194、147和125个月的透析。分析的非肿瘤组织或其他癌组织,包括透析特异性癌,均未发现VHL基因突变。
这些结果表明,VHL肿瘤抑制基因突变与长期透析相关的透明细胞癌有关。在本文研究的任何透析特异性RCC中均未发现VHL基因突变。